(RINF) – A team of researchers plan to investigate the potential benefits of ecstasy in treating Post Traumatic Stress Disorder (PTSD) sufferers.
Psychiatrists and psychologists in Vancouver will be testing the efficacy of medical-grade 3,4-methylenedioxy-methamphetamine (MDMA) and how it might assist patients.
The study will be conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS) and will be headed by chairman Mark Haden, a UBC public health adjunct professor who became interested in the use f psychedelics as possible treatments when a former patient recovered from heroin addiction by using a hallucinogenic substance.
MDMA acts by influencing neurotransmitters, serotonin, dopamine, and norepinephrine.
Despite now being illegal in many regions, the chemical was first used in the 1970s, as an aid in psychotherapy, although without the support of clinical trial research and is currently in clinical trials as a possible aid to treat anxiety in terminal cancer patients.